KELIX bio’s deal for PHI backed by DPI and CDC

Image Credit: Pixabay

The acquisition of Pharmaceutical Institute, (PHI) by KELIX bio is being funded by a second round of funding led by Development Partners International (or DPI) and CDC Group, two of the platform businesses’ three original backers. The deal for the Morocco-headquartered generic and therapeutic pharmaceutical business was agreed last week with as much as $200 million in financing being provided to complete the transaction which is expected to close before the end of the month once the necessary regulatory and other approvals have been granted.

This latest acquisition is the fourth made by KELIX bio, a build-and-buy pharmaceutical platform founded in 2020 by DPI, CDC, and the European Bank for Reconstruction & Development to meet the demand for affordable, specialty drugs across Africa. The business grew rapidly last year, posting an increase of 44% in its revenues, and reports a strong pipeline of acquisition targets as well as strategic R&D and cross-market distribution opportunities. So far, the platform has been capitalized with $450 million by its backers, who have plans to invest as much as $300 million more to support KELIX bio‘s future M&A plans.

To read this article, you must be a paid subscription member. (Current members login here)


Reserve your digital subscription today

Join now for $35 per month

Join now for $395 per year

for access to:

  • Weekly newsletter with original and curated news, analysis and perspective
  • Africa’s private capital deals, fund raises and the investment firms and executives involved
  • Portfolio company news that impacts value and stakeholder participation
  • Job moves and partnerships between leading market participants
  • Exclusive access to Africa Capital Digest’s full content archive

If you’d like more information on exceptional value group subscriptions for your colleagues and teams, please contact Teresa Hall at thall[at] today.